In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was $16.42 for the day, up 8.60% from the previous closing price of $15.12. In other words, the price has increased by $8.60 from its previous closing price. On the day, 1.04 million shares were traded. NAMS stock price reached its highest trading level at $16.55 during the session, while it also had its lowest trading level at $14.92.
Ratios:
Our analysis of NAMS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.08 and its Current Ratio is at 8.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $48.
On March 14, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $35.Scotiabank initiated its Sector Outperform rating on March 14, 2024, with a $35 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 11 ’25 when NAP PoolCo B.V. bought 1,433,193 shares for $15.12 per share.
Topper James N bought 1,135 shares of NAMS for $25,521 on Mar 26 ’25. The Director now owns 3,013,569 shares after completing the transaction at $22.49 per share. On Mar 26 ’25, another insider, Michael H. Davidson, who serves as the Affiliate of the company, bought 12,258 shares for $23.41 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 1803211520 and an Enterprise Value of 969466496. For the stock, the TTM Price-to-Sale (P/S) ratio is 39.58 while its Price-to-Book (P/B) ratio in mrq is 2.34. Its current Enterprise Value per Revenue stands at 21.277 whereas that against EBITDA is -5.503.
Stock Price History:
The Beta on a monthly basis for NAMS is 0.14, which has changed by -0.15794873 over the last 52 weeks, in comparison to a change of 0.07019031 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is -19.60%, while the 200-Day Moving Average is calculated to be -17.96%.
Shares Statistics:
NAMS traded an average of 1.01M shares per day over the past three months and 1465620 shares per day over the past ten days. A total of 108.06M shares are outstanding, with a floating share count of 61.06M. Insiders hold about 44.40% of the company’s shares, while institutions hold 48.02% stake in the company. Shares short for NAMS as of 1743379200 were 5341471 with a Short Ratio of 5.29, compared to 1740700800 on 3040999. Therefore, it implies a Short% of Shares Outstanding of 5341471 and a Short% of Float of 7.32.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
